CALCIUM ANTAGONISTS PREVENT MONOCYTE MODIFICATION OF LOW DENSITY LIPOPROTEINS AND ENDOTHELIAL CELL-INDUCED

Low density lipoprotein (LDL) incubated in the presence of the calcium antagonists verapamil, nifedipine and flunarizine were more resistant than control LDL to human monocyte- or endothelial cell-induced modification, as assessed by electrophoretic mobility in agarose gel, thiobarbituric acid reactive substance content, and degradation by 5774 macrophages. The efficiency of the drugs was: Aunarizine > nifedipine > veraparnil. Moreover, a 24 h preculture with calcium antagonists significantly impaired the ability of cells to modify LDL in the absence of the drugs. All the studied drugs also inhibited copper-induced autooxidation of LDL. None of the studied calcium antagonists. at concentrations up to M, significantly reacted with free radicals as assessed by the 1 ,I-diphenyl-2-picrylhydrazyl test. It is suggested that such a protective effect of calcium antagonists against LDL peroxidation could play a role in the previously reported antiatherogenic effect of these drugs.

[1]  L. McLean,et al.  Antioxidant activity of probucol and its effects on phase transitions in phosphatidylcholine liposomes. , 1990, Biochimica et biophysica acta.

[2]  S. Rankin,et al.  The oxidative modification of low-density lipoproteins by macrophages. , 1990, The Biochemical journal.

[3]  M. Auclair,et al.  Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol. , 1990, Biochimica et biophysica acta.

[4]  D. Janero,et al.  Antiperoxidant effects of dihydropyridine calcium antagonists. , 1989, Biochemical pharmacology.

[5]  A. Gown,et al.  Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. , 1989, The American journal of pathology.

[6]  M. Auclair,et al.  Carbon disulfide modification and impaired catabolism of low density lipoprotein. , 1989, Atherosclerosis.

[7]  V. Mišík,et al.  Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrhythmic-antihypoxic drug stobadine. , 1989, Biochimica et biophysica acta.

[8]  D. Janero,et al.  Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. , 1988, Biochemical pharmacology.

[9]  G. Schmitz,et al.  Ca++ Antagonists and ACAT Inhibitors Promote Cholesterol Efflux from Macrophages by Different Mechanisms: I. Characterization of Cellular Lipid Metabolism , 1988, Arteriosclerosis.

[10]  K. Yagi.  Lipid peroxides and human diseases. , 1987, Chemistry and physics of lipids.

[11]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Nayler,et al.  Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. , 1987, The American journal of cardiology.

[13]  A. Kuroiwa,et al.  Suppression of Atherosclerosis in Cholesterol‐Fed Rabbits by Diltiazem Injection , 1986, Arteriosclerosis.

[14]  S. Young,et al.  Probucol inhibits oxidative modification of low density lipoprotein. , 1986, The Journal of clinical investigation.

[15]  D. Morel,et al.  Monocytes and Neutrophils Oxidize Low Density Lipoprotein Making It Cytotoxic , 1985, Journal of leukocyte biology.

[16]  E. Leitersdorf,et al.  Verapamil Enhances Receptor‐Mediated Endocytosis of Low Density Lipoproteins by Aortic Cells in Culture , 1985, Arteriosclerosis.

[17]  A. Chait,et al.  Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. , 1984, The Journal of clinical investigation.

[18]  D. Morel,et al.  Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.

[19]  J. Rouleau,et al.  Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. , 1983, Journal of the American College of Cardiology.

[20]  S. Nagatsuka,et al.  Effects of membrane-stabilizing agents, cholesterol and cepharanthin, on radiation-induced lipid peroxidation and permeability in liposomes , 1982 .

[21]  D. Steinberg,et al.  Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Brown,et al.  Regulation of plasma cholesterol by lipoprotein receptors. , 1981, Science.

[23]  K. Nilsson,et al.  Establishment and characterization of a human histiocytic lymphoma cell line (U‐937) , 1976, International journal of cancer.

[24]  M. Brown,et al.  Receptor-mediated control of cholesterol metabolism. , 1976, Science.

[25]  M. Cohn,et al.  Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity. , 1975, Journal of immunology.

[26]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[27]  D. Bilheimer,et al.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. , 1972, Biochimica et biophysica acta.

[28]  M. S. Blois,et al.  Antioxidant Determinations by the Use of a Stable Free Radical , 1958, Nature.

[29]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[30]  J. Mazière,et al.  The effects of perhexiline maleate on low density lipoprotein processing and cholesterol metabolism in cultured human fibroblasts , 2004, European Journal of Clinical Pharmacology.

[31]  U. Steinbrecher,et al.  Role of oxidatively modified LDL in atherosclerosis. , 1990, Free radical biology & medicine.

[32]  R. Paoletti,et al.  Calcium antagonists and low density lipoproteins metabolism by human fibroblasts and by human hepatoma cell line HEP G2. , 1986, Pharmacological research communications.